NCBiotech News

Raleigh’s Eva Garland Consulting, LLC has expanded its partnership with the National Institutes of Health, thanks to a newly awarded contract.

Pfizer, the international biopharmaceutical giant, is expanding its gene therapy program with the purchase of a Durham property that will become a clinical manufacturing facility.

NIH has launched a massive effort to develop better flu vaccines, awarding the Duke Human Vaccine Institute three contracts worth up to $400 million over seven years.

RTP's CivaTech Oncology has received marketing approval from the FDA for its new CivaDerm skin cancer treatment "bandage."

Durham's Ribometrix, started with funding help from NCBiotech, will partner with Vertex Pharmaceuticals of Boston to discover and develop drug candidates in a deal that could ultimately be worth more than $700 million to Ribometrix.

The U.S. Department of Health and Human Services has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceutical’s approved antiviral influenza therapy, RAPIVAV.

Knowledge is power. Work smarter not harder. Both principles drove the third annual Informing Innovation 2019 event hosted recently by the Life Science Intelligence team at the North Carolina Biotechnology Center.

Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, joins companies from the U.S., Belgium, the U.K. and Spain named to the prestigious "Fierce 15" listing of the world's hottest biotech companies.

Type 2 diabetes patients may soon have an option to inhale insulin through a device from Durham's Aerami Therapeutics that acts faster and lasts longer than Lilly’s injected insulin.

A $1.1 million U.S. Department of Defense grant will support Morrisville-based Novan’s efforts to develop a new defense against cervical cancer.

Hanging on to North Carolina's dominance in agricultural technology requires continued investment and innovation, said panelists at the North Carolina Biotechnology Center’s September AgTech Professional Forum.

Durham’s Mycovia Pharmaceuticals has emerged as the winner over nine finalist life science startups from across the nation vying for recognition in the “Buzz of BIO” Late Stage Leaders competition, part of the BIO Investor Forum taking place in San Francisco in October. 

Applications for the Vicky Amidon Innovation Grant in Lung Cancer Research Award are due Oct. 1.

The NCBiotech Agriculture Sector Development team is partnering with local agriculture organizations to highlight women in agriculture across North Carolina.

Precision BioSciences, a genome-editing company based in Durham, has received authorization from the U.S. Food and Drug Administration to advance its second genome-edited cancer therapy to clinical trials.